Genome editing by CRISPR-Cas9 holds great promise for gene therapy but raises safety concerns due to DNA damage at the targeted site. Here, authors develop an integrated approach combining scSNP-DNAseq and LOH assays to monitor CRISPR-induced genotoxicity in primary cells.
- Julian Boutin
- Sabrina Fayet
- Aurélie Bedel
